SpringWorks Therapeutics, Inc. (SWTX)

25,49 +0,20 (+0,79%) Börsenschluss: 04:00PM EDT

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490
https://www.springworkstx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 227

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Saqib Islam J.D.	CEO & Director	1,13M	N/A	1970
Mr. Francis I. Perier Jr., M.B.A.	Chief Financial Officer	674,85k	N/A	1960
Dr. Badreddin Edris Ph.D.	Chief Operating Officer	844,74k	N/A	1987
Mr. Bhavesh Ashar	Chief Commercial Officer	821,61k	N/A	1966
Mr. Michael P. Nofi	Chief Accounting Officer	N/A	N/A	1971
Ms. Kim Diamond	VP of Communications & Investor Relations	N/A	N/A	N/A
Mr. Herschel S. Weinstein J.D.	Gen. Counsel & Sec.	N/A	N/A	1956
Mr. Daniel J. Pichl	Chief People Officer	N/A	N/A	1983
Dr. L. Mary Smith PH.D.	Chief Devel. Officer	N/A	N/A	1967
Dr. James Cassidy M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate Governance

SpringWorks Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. März 2023, lautet 9. Die grundlegenden Scores sind Audit: 7, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.